Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 15/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 7/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.34 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.34 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16129064 | 0.90 | PRMT1 (0.37) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL16129067 | 0.90 | PRMT1 (0.38) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL19904792 | 0.89 | PRMT1 (0.45) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL16124050 | 0.89 | PRMT1 (0.38) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL16128991 | 0.89 | PRMT1 (0.38) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL19432272 | 0.88 | PRMT1 (0.37) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL16129112 | 0.88 | PRMT1 (0.37) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL16124057 | 0.88 | PRMT1 (0.37) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL19428302 | 0.87 | PRMT1 (0.36) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL19431940 | 0.87 | PRMT1 (0.36) | PRMT1CARM1PRMT6PRMT8PRMT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970134-B1 | PYRAZOLE DERIVATIVES AS PRMT1 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160039767-A1 | PYRAZOLE DERIVATIVES AS PRMT1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-02-11 | — | — | US | disclosed |
| US-8952026-B2 | PRMT1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140288140-A1 | PRMT1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039767-A1 | PYRAZOLE DERIVATIVES AS PRMT1 INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PRMT1 1/4885CARM1 8/4885PRMT6 5/4885 |
| US-20140288140-A1 | PRMT1 INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT6 | PRMT1 1/4885CARM1 8/4885PRMT6 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.